Table of Contents
Lymphoma
Volume 2014, Article ID 205215, 12 pages
http://dx.doi.org/10.1155/2014/205215
Research Article

Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA

1Service d’Hématologie Clinique, Centre Hospitalier Lyon-Sud, Hospices Civiles de Lyon, 69310 Pierre Bénite, France
2Service d’Hématologie, CHU de Nice, 06000 Nice, France
3Service d’Hématologie Clinique, CHU de Reims, 51100 Reims, France
4Service d’Hématologie, General Hospital St. Jan, B8000 Brugge, Belgium
5Service d’Onco-hématologie, Hôpital Saint Louis, 1700 La Rochelle, France
6Service d’Hématologie Clinique, Institut Jules Bordet, 1000 Bruxelles, Belgium
7Service d’Hématologie, Centre Hospitalier de Mulhouse Hasenrein, 68100 Mulhouse, France
8Service d’Hématologie, Centre Hospitalier Necker, 75015 Paris, France
9Institut Régional du Cancer, 34070 Montpellier, France

Received 21 September 2013; Accepted 17 November 2013; Published 16 January 2014

Academic Editor: Umberto Vitolo

Copyright © 2014 Clémentine Sarkozy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Coiffier, E. Lepage, J. Brière et al., “Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 4, pp. 235–242, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Coiffier, C. Thieblemont, E. van den Neste et al., “Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte,” Blood, vol. 116, no. 12, pp. 2040–2045, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Pfreundschuh, J. Schubert, M. Ziepert et al., “Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60),” The Lancet Oncology, vol. 9, no. 2, pp. 105–116, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Pfreundschuh, E. Kuhnt, L. Trümper et al., “CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group,” The Lancet Oncology, vol. 12, no. 11, pp. 1013–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Pfreundschuh, L. Trümper, A. Österborg et al., “CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group,” The Lancet Oncology, vol. 7, no. 5, pp. 379–391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. T. M. Habermann, E. A. Weller, V. A. Morrison et al., “Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 24, no. 19, pp. 3121–3127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. O. Fitoussi, K. Belhadj, N. Mounier et al., “Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA,” Haematologica, vol. 96, no. 8, pp. 1136–1143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Récher, B. Coiffier, C. Haioun et al., “Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial,” The Lancet, vol. 378, no. 9806, pp. 1858–1867, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Tilly, E. Lepage, B. Coiffier et al., “Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma,” Blood, vol. 102, no. 13, pp. 4284–4289, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. “A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project,” The New England Journal of Medicine, vol. 329, no. 14, pp. 987–994, 1993.
  11. E. Roman and A. G. Smith, “Epidemiology of lymphomas,” Histopathology, vol. 58, no. 1, pp. 4–14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. S. C. Larsson and A. Wolk, “Body mass index and risk of non-Hodgkin's and Hodgkin's lymphoma: a meta-analysis of prospective studies,” European Journal of Cancer, vol. 47, no. 16, pp. 2422–2430, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. Q. Li, E. T. Chang, B. A. Bassig et al., “Body size and risk of Hodgkin's lymphoma by age and gender: a population-based case-control study in Connecticut and Massachusetts,” Cancer Causes & Control, vol. 24, no. 2, pp. 287–295, 2012. View at Publisher · View at Google Scholar
  14. A. V. Patel, W. R. Diver, L. R. Teras, B. M. Birmann, and S. M. Gapstur, “Body mass index, height, and risk of lymphoid neoplasms in a large US cohort,” Leukemia & Lymphoma, vol. 54, no. 6, pp. 1221–1227, 2013. View at Publisher · View at Google Scholar
  15. S. Riihijärvi, M. Taskinen, M. Jerkeman, and S. Leppä, “Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy,” European Journal of Haematology, vol. 86, no. 2, pp. 124–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Müller, N. Murawski, M. H. J. Wiesen et al., “The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL,” Blood, vol. 119, no. 14, pp. 3276–3284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. E. E. Calle, C. Rodriguez, K. Walker-Thurmond, and M. J. Thun, “Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults,” The New England Journal of Medicine, vol. 348, no. 17, pp. 1625–1638, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Jones, L. E. Fayad, L. S. Elting, and M. A. Rodriguez, “Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma,” Leukemia & Lymphoma, vol. 51, no. 9, pp. 1649–1657, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Hasselblom, B. Ridell, H. Nilsson-Ehle, and P.-O. Andersson, “The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma—a population-based study,” Leukemia & Lymphoma, vol. 48, no. 4, pp. 736–745, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Ngo, S.-W. Hee, L.-C. Lim et al., “Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab,” Leukemia & Lymphoma, vol. 49, no. 3, pp. 462–469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Delarue, H. Tilly, G. Salles et al., “R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): final analysis of the LNH03-6B GELA study,” Journal of Clinical Oncology, vol. 30, 2012. View at Google Scholar
  22. C. Agostinelli, C. Mueller, S. Zeynalova et al., “Evidence for rituximab (R) underdosing in subpopulations of elderly patients with DLBC: results of the RICOVER-60 study of the DSHNHL,” Journal of Clinical Oncology, vol. 30, supplement 1, p. 370, 2012. View at Google Scholar
  23. N. Murawski, G. Held, S. Zeynalova et al., “Improved outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab applications given over an extended period (SMARTE-R-CHOP-14 DSHNHL trial) is due to better results of male patients,” Haematologica, vol. 97, p. 109, 2012. View at Google Scholar
  24. C. Gisselbrecht, N. Schmitz, N. Mounier et al., “Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma,” Journal of Clinical Oncology, vol. 30, no. 36, pp. 4462–4469, 2012. View at Google Scholar
  25. A. M. Carella, C. A. de Souza, S. Luminari et al., “Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study,” Leukemia & Lymphoma, vol. 54, no. 1, pp. 53–57, 2013. View at Publisher · View at Google Scholar
  26. U. Jäger, M. Fridrik, M. Zeitlinger et al., “Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response,” Haematologica, vol. 97, no. 9, pp. 1431–1438, 2012. View at Google Scholar
  27. I. Ordás, D. R. Mould, B. G. Feagan, and W. J. Sandborn, “Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms,” Clinical Pharmacology and Therapeutics, vol. 91, no. 4, pp. 635–646, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Jilma-Stohlawetz, R. A. Reiter, S. Panzer, M. Horvath, W. Eppel, and B. Jilma, “Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK,” Transfusion and Apheresis Science, vol. 33, no. 2, pp. 135–140, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-F. Lu, R. Bruno, S. Eppler, W. Novotny, B. Lum, and J. Gaudreault, “Clinical pharmacokinetics of bevacizumab in patients with solid tumors,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 5, pp. 779–786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. L. B. Saltz, S. Clarke, E. Díaz-Rubio et al., “Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2013–2019, 2008. View at Google Scholar
  31. J. R. Brahmer, S. E. Dahlberg, R. J. Gray et al., “Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599,” Journal of Thoracic Oncology, vol. 6, no. 1, pp. 103–108, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. C. M. Ng, R. Bruno, D. Combs, and B. Davies, “Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial,” Journal of Clinical Pharmacology, vol. 45, no. 7, pp. 792–801, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Gandhi, F. Aweeka, R. M. Greenblatt, and T. F. Blaschke, “Sex differences in pharmacokinetics and pharmacodynamics,” Annual Review of Pharmacology and Toxicology, vol. 44, pp. 499–523, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. O. P. Soldin and D. R. Mattison, “Sex differences in pharmacokinetics and pharmacodynamics,” Clinical Pharmacokinetics, vol. 48, no. 3, pp. 143–157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Z. Harris, S. M. Tsunoda, P. Mroczkowski, H. Wong, and L. Z. Benet, “The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics,” Clinical Pharmacology and Therapeutics, vol. 59, no. 4, pp. 429–435, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. O. Schmetzer and A. Flörcken, “Sex differences in the drug therapy for oncologic diseases,” Handbook of Experimental Pharmacology, no. 214, pp. 411–442, 2012. View at Publisher · View at Google Scholar
  37. N. A. Dobbs, C. J. Twelves, H. Gillies, C. A. James, P. G. Harper, and R. D. Rubens, “Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry,” Cancer Chemotherapy and Pharmacology, vol. 36, no. 6, pp. 473–476, 1995. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Salles, J. F. Seymour, F. Offner et al., “Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial,” The Lancet, vol. 377, no. 9759, pp. 42–51, 2011. View at Publisher · View at Google Scholar
  39. J. L. Villano, M. Koshy, H. Shaikh, T. A. Dolecek, and B. J. McCarthy, “Age, gender, and racial differences in incidence and survival in primary CNS lymphoma,” British Journal of Cancer, vol. 105, no. 9, pp. 1414–1418, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Hasenclever, V. Diehl, J. O. Armitage et al., “A prognostic score for advanced Hodgkin's disease,” The New England Journal of Medicine, vol. 339, no. 21, pp. 1506–1514, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. K. K. Khamly, V. J. Thursfield, M. Fay et al., “Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood,” International Journal of Cancer, vol. 125, no. 2, pp. 426–431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Joosse, S. Collette, S. Suciu et al., “Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials,” Journal of Clinical Oncology, vol. 30, no. 18, pp. 2240–2247, 2012. View at Publisher · View at Google Scholar
  43. G. Svensson, S.-B. Ewers, O. Ohlsson, and H. Olsson, “Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on gender,” The Clinical Respiratory Journal, vol. 7, no. 1, pp. 91–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. C. A. Gilbert and J. M. Slingerland, “Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression,” Annual Review of Medicine, vol. 64, pp. 45–57, 2013. View at Google Scholar
  45. K. Y. Wolin, K. Carson, and G. A. Colditz, “Obesity and cancer,” Oncologist, vol. 15, no. 6, pp. 556–565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. K. R. Carson, N. L. Bartlett, J. R. McDonald et al., “Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 30, no. 26, pp. 3217–3222, 2012. View at Google Scholar